Last updated: May 2, 2026
Who supplies the active pharmaceutical ingredient (API) for WEGOVY HD?
WEGOVY HD is a high-dose, subcutaneous formulation of semaglutide (GLP-1 receptor agonist). Publicly disclosed supplier detail for the semaglutide API manufacturing chain depends on jurisdictional filings, product labeling, and licensing disclosures. Without jurisdiction-specific sourcing tables or direct access to private supply agreements, supplier identification cannot be completed to a verifiable, decision-grade standard.
Who supplies the finished drug product manufacturing for WEGOVY HD?
WEGOVY branded products in this class are manufactured under Novo Nordisk’s global supply network and contract manufacturing partners, but WEGOVY HD-specific finished-dose plant attribution is not fully determinable from universally accessible public records at the level required to name specific facilities and suppliers without risking incorrect assignment.
Which suppliers provide the packaging and device components (pen/needle system) for WEGOVY HD?
WEGOVY is delivered via a pen injector system. Pen dosing, container closure components, and needle systems typically involve specialized device suppliers and packaging vendors. However, device-component supplier identification for WEGOVY HD is not consistently disclosed in public sources in a facility-and-vendor form suitable for procurement or investment decisions.
What supplier information is publicly documented for semaglutide-based injection products?
Public sources generally confirm:
- Product manufacturer/marketing authorization holder: Novo Nordisk (brand owner for WEGOVY).
- Active ingredient: semaglutide.
- Dosage form and route: subcutaneous injection.
- Regulatory approvals and labeling: confirm composition and presentation, not always the full upstream supplier chain.
These disclosures do not, by themselves, produce a complete and accurate vendor roster for:
- semaglutide API makers
- drug-product manufacturing plants for the “HD” presentation
- packaging and pen/needle component suppliers specific to “WEGOVY HD”
Decision-grade supplier mapping for WEGOVY HD
A verifiable supplier map for WEGOVY HD requires at least one of the following public, citable inputs:
- Finished product manufacturing site and labeling references tied to WEGOVY HD’s specific strength
- Regulatory assessment documents (CMC or variations) that list manufacturing sites and named contract partners for that exact presentation
- Marketing authorization country documentation that enumerates manufacturer and site-of-manufacture fields for the “HD” strength
- Pen device component supplier disclosures tied to that exact product strength and fill configuration
Those items are not available in the material provided, so supplier names cannot be stated.
Key Takeaways
- WEGOVY HD contains semaglutide for subcutaneous injection, with finished-dose and device delivery under Novo Nordisk’s branded program.
- Publicly accessible information is sufficient to confirm the brand owner and drug substance identity, but not sufficient to accurately and completely name specific API, finished-product, and packaging/device suppliers for WEGOVY HD.
- A complete supplier list requires presentation-specific regulatory or labeling documents that explicitly identify the manufacturing sites and named suppliers for the “HD” strength.
FAQs
-
Is WEGOVY HD manufactured by Novo Nordisk?
The brand owner is Novo Nordisk, but presentation-specific finished-dose plant attribution for the “HD” strength is not fully verifiable from the information available here.
-
Who makes the semaglutide API used in WEGOVY?
Semaglutide is the API. Specific semaglutide API suppliers for WEGOVY HD are not verifiably identified in the material available here.
-
Who supplies the pen injector device used for WEGOVY HD?
WEGOVY uses a pen injector system, but the device-component vendor chain for the “HD” presentation is not verifiably disclosed in the material available here.
-
Do regulatory labels list supplier factories and vendors?
Labels commonly list the marketing authorization holder and may list manufacturers, but they often do not enumerate upstream API vendors or device component suppliers.
-
Can procurement plans rely on generic WEGOVY supplier data for “WEGOVY HD”?
They generally should not; the “HD” presentation can differ in strength, fill, and packaging configuration, which changes the relevant manufacturing and packaging chain.
References (APA)
[1] Novo Nordisk. (n.d.). WEGOVY (semaglutide) prescribing information/labeling (public product documents vary by country). Novo Nordisk.
